A new study led by researchers at the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer ...
“TY1 is the first exomer – a new class of drugs that address tissue damage in unexpected ways.” TY1 has the structure of existing RNA drugs, and works like its natural version – amplifying the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results